Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Re MC, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Grima P, Francisci D, Mastroianni C, Antinori A, Trezzi M, Lisi L, Navarra P, Canovari B, D'Arminio Monforte A, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A; for GUSTA trial study group.
Rossetti B, et al.
PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.
PLoS One. 2017.
PMID: 29161288
Free PMC article.
Clinical Trial.